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Ab

:   antibody

CT

:   computed tomography

DFPP

:   double‐filtration plasmapheresis

DVT

:   deep vein thrombosis

EIV

:   external illiac vein

HD

:   hemodialysis

HIT

:   heparin‐induced thrombocytopenia

IVC

:   inferior vena cava

KTx

:   kidney transplantation

MMF

:   mycophenolate mofetil

mPSL

:   methylprednisolone

PE

:   pulmonary embolism

Tac

:   tacrolimus

TMA

:   thrombotic microangiopathy

VTE

:   venous thromboembolism

Keynote messageKTx without perioperative anticoagulation therapy is a well‐tolerated treatment option for end‐stage kidney disease patients with past history of HIT after disappearance of anti‐HIT Ab.

Introduction {#iju512148-sec-0005}
============

HIT is an Ab‐mediated acquired prothrombotic state induced by heparin exposure. The risk of HIT was reported in approximately 3% of patients who received heparin exposure.[1](#iju512148-bib-0001){ref-type="ref"} While some cases of HIT in KTx were reported, the risk of thromboembolic diseases in KTx with HIT has not been determined.[2](#iju512148-bib-0002){ref-type="ref"}, [3](#iju512148-bib-0003){ref-type="ref"}, [4](#iju512148-bib-0004){ref-type="ref"}, [5](#iju512148-bib-0005){ref-type="ref"}, [6](#iju512148-bib-0006){ref-type="ref"} There were a few case reports on successful KTx in patients with a history of HIT; however, these patients received anticoagulants, although it is not required during typical KTx.[4](#iju512148-bib-0004){ref-type="ref"}, [5](#iju512148-bib-0005){ref-type="ref"}, [6](#iju512148-bib-0006){ref-type="ref"} We report a case of successful living KTx without perioperative anticoagulation in a patient with end‐stage renal disease with a history of HIT.

Case presentation {#iju512148-sec-0006}
=================

A 63‐year‐old male patient with end‐stage renal disease was referred to our hospital for living KTx by donation from his wife. He started HD 2 months before being referred to our hospital. Initially, unfractionated heparin was infused as anticoagulant during HD; however, clotting in the dialysis membrane had frequently occurred, and thrombocytopenia had been gradually exacerbated (Fig. [1](#iju512148-fig-0001){ref-type="fig"}). Serum anti‐HIT Ab level was examined for the suspicion of HIT, and seropositivity of anti‐HIT Ab led to the diagnosis of HIT type II. Unfractionated heparin was discontinued and changed to argatroban as the anticoagulant during HD. Thrombocytopenia gradually improved, and events of clotting in the HD membrane also decreased after changing the anticoagulant. Negative conversion of serum anti‐HIT Ab was confirmed 4 months after unfractionated heparin cessation.

![Transition of platelet count and titer of anti‐HIT Ab after HD initiation. The day of HD initiation was set to day 0. The titer of anti‐HIT Ab had been evaluated until day 149 and then examined at our hospital.](IJU5-3-86-g001){#iju512148-fig-0001}

Preservation of seronegative status and absence of thrombotic complications were confirmed by enhanced CT, and then, living KTx between spouses was performed. Maintenance HD therapy and three‐time DFPP against flowcytometry B‐cell crossmatch positivity due to the presence of donor‐specific anti‐HLA Ab (mean fluorescence intensity was 1156) were conducted before KTx using argatroban. Both heparinization and application of medical equipment containing heparin were avoided during the operation. No anticoagulant was administered even during vessel suturing. The graft kidney functioned immediately, and maintenance HD was withdrawn (Fig. [2](#iju512148-fig-0002){ref-type="fig"}). No anticoagulant was administered postoperatively. Immunosuppression consisting of steroid, MMF, and Tac and induction therapy consisting of basiliximab and single dose of 200 mg rituximab were adopted for the patient. No thromboembolic adverse event has occurred, and graft function is well‐maintained 1 year after transplantation.

![Platelet count, serum creatinine level, and immunosuppressive regimen of the recipient during and after KTx. The day of KTx was set to day 0.](IJU5-3-86-g002){#iju512148-fig-0002}

Discussion {#iju512148-sec-0007}
==========

Almost all HD patients are exposed to heparin, which is used as an anticoagulant during each treatment session, and chronic intermittent heparin exposure is associated with developing anti‐heparin Ab, which is observed in approximately 10% of these patients.[7](#iju512148-bib-0007){ref-type="ref"} Although there is a high prevalence of anti‐heparin Ab in HD patients, thromboembolic complications with thrombocytopenia do not always develop even in this status.[7](#iju512148-bib-0007){ref-type="ref"} The pretest probability of HIT uses the four *T*'s scoring system: degree of thrombocytopenia, timing of thrombocytopenia with respect to heparin exposure, occurrence of thrombotic complications, and absence of alternative explanations for thrombocytopenia.[5](#iju512148-bib-0005){ref-type="ref"}, [8](#iju512148-bib-0008){ref-type="ref"} Our patient did not present with systemic thromboembolic complications but had clotting in the dialysis membrane and more than 50% platelet count fall after heparin exposure without other detectable causes of thrombocytopenia. Both the presence of anti‐heparin Ab with these typical clinical symptoms and recovery of thrombocytopenia after replacement of unfractionated heparin with argatroban support the diagnosis of HIT type II in this case.

We found 10 cases of HIT in KTx[3](#iju512148-bib-0003){ref-type="ref"}, [4](#iju512148-bib-0004){ref-type="ref"}, [5](#iju512148-bib-0005){ref-type="ref"}, [6](#iju512148-bib-0006){ref-type="ref"}, [9](#iju512148-bib-0009){ref-type="ref"}, [10](#iju512148-bib-0010){ref-type="ref"}, [11](#iju512148-bib-0011){ref-type="ref"}, [12](#iju512148-bib-0012){ref-type="ref"}, [13](#iju512148-bib-0013){ref-type="ref"}, [14](#iju512148-bib-0014){ref-type="ref"} (Table [1](#iju512148-tbl-0001){ref-type="table"}). Seven of the 11 patients were diagnosed preoperatively on the basis of the thrombotic complications, while four patients were diagnosed during or after transplantation. All four patients who had not been diagnosed before transplantation and one patient who underwent a successful retransplantation after an initial HIT with graft loss developed thrombotic complications requiring anticoagulation therapy after KTx. Two of the five patients lost graft function due to thrombosis. Six patients diagnosed as having HIT before transplantation did not develop thrombotic complications except for one patient with antiphospholipid Ab syndrome.[11](#iju512148-bib-0011){ref-type="ref"} The anti‐HIT Ab titer became negative before KTx in all patients except in one who received heart and KTxs. These reports indicate that a history of HIT is not a contraindication for KTx and that the period of negative seroconversion of anti‐HIT Ab may be the preferable time for transplantation. However, all these patients, except our patient, received anticoagulants during the peritransplantation period to minimize the risk of thromboembolic complications due to HIT despite the negative seroconversion of anti‐HIT Ab. Furthermore, we could not find a case of other organ transplantation without anticoagulants during the peritransplantation period.

###### 

Review of literature on KTx with HIT

  Organ                 Case                  Diagnosis of HIT   HIT Ab at KTx   Anticoaglant therapy during operatoin   Thrombotic complication             Author          Year
  --------------------- --------------------- ------------------ --------------- --------------------------------------- ----------------------------------- --------------- ------
  Kidney                19 years old male     After KTx          N/A             Heparin                                 TMA in transplanted kidney          Anderegg BA     2005
  Kidney                17 years old male     Before KTx         Negative        Recombinant hirudin                     None                                John U          2006
  Kidney                22 years old female   After KTx          N/A             Heparin                                 Thrombosis from IVC to EIV and PE   Dracopoulos S   2007
  Kidney                68 years old male     After KTx          N/A             Heparin                                 DVT and PE                          Maldonado A     2009
  Kidney                50 years old male     Before KTx         Negative        Coumadin                                DVT and PE                          Muzaffar M      2012
  Kidney                67 years old female   During KTx         N/A             Dabigatran                              DVT                                 Sakakibara S    2014
  Kidney                23 years old female   Before KTx         N/A             Bivalirudin                             None                                Podolak B       2014
  Kidney                64 years old male     Before KTx         Negative        None                                    None                                Our case        2019
  Pancreas and kidney   36 years old female   Before KTx         Negative        Dabigatran                              None                                Jozwik A        2018
  Liver and kidney      58 years old male     Before KTx         Negative        Argatroban                              None                                Taguchi K       2019
  Heart and kidney      49 years old female   Before KTx         Positive        Bivalirudin                             None                                Choxi AA        2017
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In patients strongly suspected of having HIT, heparin should be immediately replaced with an appropriate anticoagulant such as argatroban.[15](#iju512148-bib-0015){ref-type="ref"}, [16](#iju512148-bib-0016){ref-type="ref"}, [17](#iju512148-bib-0017){ref-type="ref"} As far as appropriate treatments for HIT are performed, anti‐HIT Ab is transient with a median time of disappearance from 50 to 80 days.[18](#iju512148-bib-0018){ref-type="ref"} Our patient showed negative conversion of anti‐HIT Ab without life‐threating thromboembolic complications 4 months after heparin cessation and administration of argatroban during HD sessions and then underwent KTx. While we avoided both heparization and application of medical equipment containing heparin during the peritransplant term to minimize the risk of thromboembolic complications due to HIT, we did not administer anticoagulants excluding argatroban during plasmapheresis before transplantation. There were several reasons why we determined the treatment policy. First, anticoagulation during the vessel clamping period in KTx is not usually necessary. Second, clinical episode of thromboembolic complications excluding clot formation in the dialysis membrane had not been observed, and absence of thromboembolic complication was confirmed by systemic enhanced CT examination. A past history of VTE is considered to be the most important risk factor determining VTE recurrence.[19](#iju512148-bib-0019){ref-type="ref"} KTx without anticoagulants may be considered for recipients who are diagnosed with HIT without systemic thromboembolism. Lastly, non‐heparin anticoagulant was considered to potentially facilitate perioperative bleeding. Argatroban is the only drug approved by Japanese health insurance as an anticoagulant for patients with HIT. No specific antidote is available for argatroban, and thus continuous administration of argatroban during the peritransplant term may make it difficult to control sudden massive bleeding. On the other hand, this is only a single case report. Further investigation including prospective large‐sized clinical studies is required to establish anticoagulant management in KTx of patients with HIT.

We successfully performed living KTx without perioperative anticoagulation in a patient with HIT. KTx without perioperative anticoagulation after disappearance of anti‐HIT Ab could be a well‐tolerated treatment option for patients with end‐stage kidney disease.
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